anastrozole has been researched along with Arthralgia in 26 studies
Arthralgia: Pain in the joint.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 9.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer." | 9.19 | COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. ( Blettner, M; Bolten, W; Hadji, P; Harbeck, N; Hindenburg, HJ; Jackisch, C; Klein, P; König, K; Kreienberg, R; Rief, W; Wallwiener, D; Zaun, S, 2014) |
| "The addition of oral risedronate in post-menopausal breast cancer patients receiving anastrozole has a favorable effect on BMD." | 9.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "Our results suggested that BMI and AI drug (letrozole versus anastrozole) were clinical predictors of arthralgia, while genetic variants rs4775936, rs9322336, rs2234693, and rs9340799 were genetic predictors of AI-induced arthralgia." | 7.96 | Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. ( Borrie, AE; Choi, YH; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, FA; Sexton, T; Teft, WA; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2020) |
| "Anastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P-glycoprotein (ABCB1) substrate." | 7.85 | Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. ( Carrillo, JA; Gervasini, G; Jara, C; Martínez, R; Olier, C; Romero, N, 2017) |
| "Although anastrozole (ANA), an aromatase inhibitor (AI), has been widely used for breast cancer patients; adverse events during ANA therapy in Japanese patients have not been reported." | 7.76 | Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. ( Ando, M; Baba, S; Dokiya, F; Douchi, T; Kosha, S; Matsuyama, Y; Ohi, Y; Rai, Y; Sagara, Y; Tamada, S, 2010) |
| "More than a third of breast cancer patients undergoing aromatase inhibitor (AI) treatment report joint pain." | 5.39 | Anastrozole-associated joint pain and other symptoms in patients with breast cancer. ( Cleeland, CS; Giordano, SH; Lu, H; Malveaux, D; Saleeba, AK; Shi, Q, 2013) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 5.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer." | 5.19 | COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. ( Blettner, M; Bolten, W; Hadji, P; Harbeck, N; Hindenburg, HJ; Jackisch, C; Klein, P; König, K; Kreienberg, R; Rief, W; Wallwiener, D; Zaun, S, 2014) |
| "The addition of oral risedronate in post-menopausal breast cancer patients receiving anastrozole has a favorable effect on BMD." | 5.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "Our results suggested that BMI and AI drug (letrozole versus anastrozole) were clinical predictors of arthralgia, while genetic variants rs4775936, rs9322336, rs2234693, and rs9340799 were genetic predictors of AI-induced arthralgia." | 3.96 | Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. ( Borrie, AE; Choi, YH; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, FA; Sexton, T; Teft, WA; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2020) |
| "Anastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P-glycoprotein (ABCB1) substrate." | 3.85 | Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. ( Carrillo, JA; Gervasini, G; Jara, C; Martínez, R; Olier, C; Romero, N, 2017) |
| "Postmenopausal women with an early breast cancer scheduled to start adjuvant endocrine therapy with an AI or tamoxifen were recruited." | 3.80 | Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. ( Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H, 2014) |
| "We conducted a prospective study including postmenopausal early breast cancer patients receiving either an aromatase inhibitor (AI) or tamoxifen." | 3.77 | Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. ( Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H, 2011) |
| " Because her arthralgia showed no improvement, powdered processed aconitine root was added." | 3.77 | A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines. ( Chino, A; Hirasaki, Y; Namiki, T; Ogawa, K; Okamoto, H; Ueda, K, 2011) |
| "Although anastrozole (ANA), an aromatase inhibitor (AI), has been widely used for breast cancer patients; adverse events during ANA therapy in Japanese patients have not been reported." | 3.76 | Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. ( Ando, M; Baba, S; Dokiya, F; Douchi, T; Kosha, S; Matsuyama, Y; Ohi, Y; Rai, Y; Sagara, Y; Tamada, S, 2010) |
| " The aim of this study was to assess the relative importance of different risk factors for treatment-emergent joint symptoms in patients assigned to anastrozole or tamoxifen as adjuvant treatment for postmenopausal breast cancer." | 3.74 | Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. ( Bianco, AR; Buzdar, AU; Cuzick, J; Eastell, R; Forbes, JF; Sapunar, F; Sestak, I, 2008) |
| "Women with hormone-receptor-positive tumours who reported vasomotor or joint symptoms at the first follow-up visit (3 months) in the ATAC trial, (which assessed tamoxifen or anastrozole for adjuvant treatment of postmenopausal breast cancer), were compared with women without these symptoms to see if there was a relation between these symptoms and subsequent recurrence." | 3.74 | Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. ( Cella, D; Cuzick, J; Fallowfield, L; Sestak, I, 2008) |
| "More than a third of breast cancer patients undergoing aromatase inhibitor (AI) treatment report joint pain." | 1.39 | Anastrozole-associated joint pain and other symptoms in patients with breast cancer. ( Cleeland, CS; Giordano, SH; Lu, H; Malveaux, D; Saleeba, AK; Shi, Q, 2013) |
| "Arthralgias have been frequently cited as the primary reason for discontinuation of AI therapy." | 1.38 | Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. ( Carro, G; Harper, A; Hui, W; Lawton, J; Menas, P; Merkel, D, 2012) |
| "With these treatments, joint pain is frequent (30% to 40%) and quite often disabling (5% to 10%)." | 1.34 | Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. ( Borg, S; De Lafontan, B; Laroche, M; Lassoued, S; Roché, H, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 18 (69.23) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, B | 1 |
| Kong, L | 1 |
| Yuan, M | 1 |
| Borrie, AE | 1 |
| Rose, FA | 1 |
| Choi, YH | 1 |
| Perera, FE | 1 |
| Read, N | 1 |
| Sexton, T | 1 |
| Lock, M | 1 |
| Vandenberg, TA | 1 |
| Hahn, K | 1 |
| Younus, J | 1 |
| Logan, D | 1 |
| Potvin, K | 1 |
| Yaremko, B | 1 |
| Yu, E | 1 |
| Lenehan, J | 1 |
| Welch, S | 1 |
| Teft, WA | 1 |
| Kim, RB | 1 |
| Niravath, P | 1 |
| Chen, B | 1 |
| Chapman, JW | 1 |
| Agarwal, SK | 1 |
| Welschhans, RL | 1 |
| Bongartz, T | 1 |
| Kalari, KR | 1 |
| Shepherd, LE | 1 |
| Bartlett, J | 1 |
| Pritchard, K | 1 |
| Gelmon, K | 1 |
| Hilsenbeck, SG | 1 |
| Rimawi, MF | 1 |
| Osborne, CK | 1 |
| Goss, PE | 1 |
| Ingle, JN | 1 |
| Shi, Q | 1 |
| Giordano, SH | 1 |
| Lu, H | 1 |
| Saleeba, AK | 1 |
| Malveaux, D | 1 |
| Cleeland, CS | 1 |
| Hadji, P | 1 |
| Jackisch, C | 1 |
| Bolten, W | 1 |
| Blettner, M | 1 |
| Hindenburg, HJ | 1 |
| Klein, P | 1 |
| König, K | 1 |
| Kreienberg, R | 1 |
| Rief, W | 1 |
| Wallwiener, D | 1 |
| Zaun, S | 1 |
| Harbeck, N | 1 |
| Mao, JJ | 1 |
| Farrar, JT | 1 |
| Bruner, D | 1 |
| Zee, J | 1 |
| Bowman, M | 1 |
| Seluzicki, C | 1 |
| DeMichele, A | 1 |
| Xie, SX | 1 |
| Lintermans, A | 2 |
| Vanderschueren, D | 1 |
| Verhaeghe, J | 2 |
| Van Asten, K | 1 |
| Jans, I | 1 |
| Van Herck, E | 1 |
| Laenen, A | 1 |
| Paridaens, R | 2 |
| Billen, J | 1 |
| Pauwels, S | 1 |
| Vermeersch, P | 1 |
| Wildiers, H | 2 |
| Christiaens, MR | 2 |
| Neven, P | 2 |
| Marchand, A | 1 |
| Georgin-Mège, M | 1 |
| Cellier, P | 1 |
| Martin, L | 1 |
| Avenel-Audran, M | 1 |
| Le Corre, Y | 1 |
| Shapiro, AC | 1 |
| Adlis, SA | 1 |
| Robien, K | 1 |
| Kirstein, MN | 1 |
| Liang, S | 1 |
| Richter, SA | 1 |
| Lerner, RE | 1 |
| Gervasini, G | 1 |
| Jara, C | 1 |
| Olier, C | 1 |
| Romero, N | 1 |
| Martínez, R | 1 |
| Carrillo, JA | 1 |
| Smith, I | 1 |
| Yardley, D | 1 |
| Burris, H | 1 |
| De Boer, R | 1 |
| Amadori, D | 1 |
| McIntyre, K | 1 |
| Ejlertsen, B | 1 |
| Gnant, M | 1 |
| Jonat, W | 1 |
| Pritchard, KI | 1 |
| Dowsett, M | 1 |
| Hart, L | 1 |
| Poggio, S | 1 |
| Comarella, L | 1 |
| Salomon, H | 1 |
| Wamil, B | 1 |
| O'Shaughnessy, J | 1 |
| Sestak, I | 2 |
| Cuzick, J | 3 |
| Sapunar, F | 1 |
| Eastell, R | 1 |
| Forbes, JF | 1 |
| Bianco, AR | 1 |
| Buzdar, AU | 1 |
| Cella, D | 1 |
| Fallowfield, L | 1 |
| Sagara, Y | 3 |
| Kosha, S | 1 |
| Baba, S | 1 |
| Dokiya, F | 1 |
| Tamada, S | 1 |
| Matsuyama, Y | 1 |
| Ohi, Y | 1 |
| Ando, M | 1 |
| Rai, Y | 1 |
| Douchi, T | 1 |
| Markopoulos, C | 1 |
| Tzoracoleftherakis, E | 1 |
| Polychronis, A | 1 |
| Venizelos, B | 1 |
| Dafni, U | 1 |
| Xepapadakis, G | 1 |
| Papadiamantis, J | 1 |
| Zobolas, V | 1 |
| Misitzis, J | 1 |
| Kalogerakos, K | 1 |
| Sarantopoulou, A | 1 |
| Siasos, N | 1 |
| Koukouras, D | 1 |
| Antonopoulou, Z | 1 |
| Lazarou, S | 1 |
| Gogas, H | 1 |
| Van Calster, B | 1 |
| Van Hoydonck, M | 1 |
| Pans, S | 1 |
| Westhovens, R | 1 |
| Henry, NL | 1 |
| Dieudonné, AS | 1 |
| Leunen, K | 1 |
| Morales, L | 1 |
| Verschueren, K | 1 |
| Timmerman, D | 1 |
| De Smet, L | 1 |
| Vergote, I | 1 |
| Nagykálnai, T | 1 |
| Landherr, L | 1 |
| Mészáros, E | 1 |
| Kanematsu, M | 1 |
| Morimoto, M | 1 |
| Honda, J | 1 |
| Nagao, T | 1 |
| Nakagawa, M | 1 |
| Takahashi, M | 1 |
| Tangoku, A | 1 |
| Sasa, M | 1 |
| Chino, A | 1 |
| Okamoto, H | 1 |
| Hirasaki, Y | 1 |
| Ueda, K | 1 |
| Ogawa, K | 1 |
| Namiki, T | 1 |
| Singh, S | 1 |
| Mesher, D | 1 |
| Richmond, B | 1 |
| Howell, A | 1 |
| Menas, P | 1 |
| Merkel, D | 1 |
| Hui, W | 1 |
| Lawton, J | 1 |
| Harper, A | 1 |
| Carro, G | 1 |
| Kubo, M | 1 |
| Onishi, H | 1 |
| Kuroki, S | 1 |
| Okido, M | 1 |
| Shimada, K | 1 |
| Yokohata, K | 1 |
| Umeda, S | 1 |
| Ogawa, T | 1 |
| Tanaka, M | 1 |
| Katano, M | 1 |
| Altundag, K | 1 |
| Dede, D | 1 |
| Harputluoglu, H | 1 |
| Gullu, I | 1 |
| Laroche, M | 1 |
| Borg, S | 1 |
| Lassoued, S | 1 |
| De Lafontan, B | 1 |
| Roché, H | 1 |
| Wengström, Y | 1 |
| Donnellan, PP | 1 |
| Douglas, SL | 1 |
| Cameron, DA | 1 |
| Leonard, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT): An in Practice Assessment of Arthralgias and Related Costs as Well as Compliance in the First Year of Anastrozole Therapy[NCT00857012] | 2,313 participants (Actual) | Observational | 2009-04-30 | Completed | |||
| Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors[NCT01509079] | Phase 2 | 116 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Randomised Effectiveness-implementation Trial for Evaluating Dietary and Manual Treatment With Osteopathic Techniques on Quality of Life and on Modulation of the Inflammatory State of Patients Diagnosed With Breast Cancer Undergoing Antiestrogenic Hormo[NCT06164119] | 600 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484] | 220 participants (Actual) | Observational | 2004-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
adherence measured with pill counts for the vitamin D at predesignated study timepoints: baseline (after run-in), 3 months and 6 months (NCT01509079)
Timeframe: average for all study ppts for: screening to baseline; baseline to 3 months; 3 month to 6 months
| Intervention | % of adherence for each treatment arm (Number) |
|---|---|
| Vitamin D3 4000 IU | 95 |
| Vitamin D3 600 IU | 95 |
(NCT01509079)
Timeframe: baseline to 6 months
| Intervention | pounds (Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.8 |
| Vitamin D3 600 IU | 1.0 |
The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | -0.2 |
| Vitamin D3 600 IU | -0.5 |
PROMIS measures physical functioning on the short form and higher scores reflect better physical functioning with 10 questions on daily activities of life on a Likert scale ranging from 5 (no problem performing activity) to 1 (cannot do activity). Range on this measure is from 50 (best)-10 (worst). (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | 0.6 |
| Vitamin D3 600 IU | 1.7 |
GLM Mean and standard deviation of Whole Body Bone Mineral Density (grams/cm2) of Trial Participants by Treatment Arm after controlling for bisphosphonate use (NCT01509079)
Timeframe: From Baseline and 6 months of D3 supplementation
| Intervention | gm/cm2 (Geometric Least Squares Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.1 |
| Vitamin D3 600 IU | 1.12 |
Difference in steady state concentrations in plasma from baseline to 6 months (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | mg/L (Mean) | |
|---|---|---|
| anastrozole | letrozole | |
| Vitamin D3 4000 IU | -1.31 | 2.16 |
| Vitamin D3 600 IU | 2.4 | -0.83 |
(NCT01509079)
Timeframe: baseline and 6 months
| Intervention | pg/ml (Geometric Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Vitamin D3 4000 IU | 2.83 | 2.94 |
| Vitamin D3 600 IU | 2.77 | 3.0 |
2 reviews available for anastrozole and Arthralgia
| Article | Year |
|---|---|
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Brea | 2011 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
8 trials available for anastrozole and Arthralgia
| Article | Year |
|---|---|
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neopl | 2018 |
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2014 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depr | 2014 |
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone De | 2016 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2017 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit | 2010 |
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Topics: Adult; Aged; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Arthralgia; Biomarkers; Bre | 2012 |
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anti-Inflammatory Agents; Aromatase Inhibitors; Arthralgia; Br | 2012 |
16 other studies available for anastrozole and Arthralgia
| Article | Year |
|---|---|
An experience of the intervention effect of individualized on the rehabilitation exercise on bone and joint pain symptoms caused by anastrozole.
Topics: Anastrozole; Arthralgia; Bone and Bones; Breast Neoplasms; Exercise Therapy; Female; Humans | 2023 |
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; Biomarkers | 2020 |
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Cohort Studies; Fe | 2013 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromat | 2014 |
Exemestane-induced radiation recall dermatitis and morbilliform rash.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Arthralgia; Carcinom | 2016 |
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; ATP Binding Cassette Transporter, Subfamil | 2017 |
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neo | 2008 |
Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Breast | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplas | 2011 |
The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Female; | 2011 |
A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
Topics: Aconitine; Aconitum; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; | 2011 |
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Inc | 2012 |
Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Ch | 2007 |
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; A | 2007 |
Aromatase inhibitors and arthralgia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Enzyme Inhibitors; Femal | 2001 |